KR880007060A - 제약 조성물 - Google Patents

제약 조성물 Download PDF

Info

Publication number
KR880007060A
KR880007060A KR870014136A KR870014136A KR880007060A KR 880007060 A KR880007060 A KR 880007060A KR 870014136 A KR870014136 A KR 870014136A KR 870014136 A KR870014136 A KR 870014136A KR 880007060 A KR880007060 A KR 880007060A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
ranitidine
formulation
ethanol
Prior art date
Application number
KR870014136A
Other languages
English (en)
Other versions
KR960008228B1 (ko
Inventor
리차드 롱 데이비드
Original Assignee
원본미기재
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10608930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880007060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 글락소 그룹 리미티드 filed Critical 원본미기재
Publication of KR880007060A publication Critical patent/KR880007060A/ko
Application granted granted Critical
Publication of KR960008228B1 publication Critical patent/KR960008228B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

내용 없음.

Description

제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 라니티딘 및(또는) 하나 이상의 그의 생리학적으로 허용되는 염의 수용액 제제물로서, 제제물이 또한 에탄올을 함유하는 것을 특징으로 하는 제약 조성물.
  2. 제1항에 있어서, 완전한 제제물에 기초해서 에탄올을 2.5% 내지 10중량%/용적% 함유하는 제약 조성물.
  3. 제1항에 있어서, 완전한 제제물에 기초해서 에탄올을 7% 내지 8중량/용적% 함유하는 제약 조성물.
  4. 제1항 내지 3항 중 어느 하나의 항에 있어서, pH6.5 내지 7.5를 갖는 제약 조성물.
  5. 제1항 내지 3항 중 어느 하나의 항에 있어서, pH6.8 내지 7.4를 갖는 제약 조성물.
  6. 제1항 내지 3항 중 어느 하나의 항에 있어서, pH7.0 내지 7.3를 갖는 제약 조성물.
  7. 제4항 내지 6항 중 어느 하나의 항에 있어서, pH를 완충염의 사용에 의해 얻는 것을 특징으로 하는 제약 조성물.
  8. 제1항 내지 7항 중 어느 하나의 항에 있어서, 경구 투여에 적합한 제약 조성물.
  9. 제8항에 있어서, 유리 염기로 표시되는 복용량 10ml당 라니티딘 20－400mg을 함유하는 제약 조성물.
  10. 제8항에 있어서, 유리 염기로 표시되는 복용량 10ml당 라니티딘 20－200mg을 함유하는 제약 조성물.
  11. 제8항에 있어서, 유리 염기로 표시되는 복용량 10ml당 라니티딘 150mg을 함유하는 제약 조성물.
  12. 제1항 내지 11항 중 어느 하나의 항에 있어서, 라니티딘을 염산염 염의 형태로 사용해서 제조한 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014136A 1986-12-12 1987-12-11 라니티딘 제약 조성물 KR960008228B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868629781A GB8629781D0 (en) 1986-12-12 1986-12-12 Pharmaceutical compositions
GB8629781 1986-12-12

Publications (2)

Publication Number Publication Date
KR880007060A true KR880007060A (ko) 1988-08-26
KR960008228B1 KR960008228B1 (ko) 1996-06-21

Family

ID=10608930

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014136A KR960008228B1 (ko) 1986-12-12 1987-12-11 라니티딘 제약 조성물

Country Status (23)

Country Link
US (1) US5068249A (ko)
JP (1) JP2590156B2 (ko)
KR (1) KR960008228B1 (ko)
AT (1) AT395373B (ko)
AU (1) AU607451B2 (ko)
BE (1) BE1000624A5 (ko)
CA (1) CA1303993C (ko)
CH (1) CH675207A5 (ko)
CZ (1) CZ281599B6 (ko)
DE (1) DE3742127C2 (ko)
DK (1) DK167842B1 (ko)
FR (1) FR2608921B1 (ko)
GB (2) GB8629781D0 (ko)
HK (1) HK19095A (ko)
IE (1) IE60618B1 (ko)
IL (1) IL84795A0 (ko)
IT (1) IT1211967B (ko)
NL (1) NL194431C (ko)
NZ (1) NZ222879A (ko)
PH (1) PH25390A (ko)
SE (1) SE504333C2 (ko)
YU (1) YU46561B (ko)
ZA (1) ZA879338B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
WO1996001129A1 (en) * 1994-07-06 1996-01-18 Farmarc Nederland B.V. Inclusion complexes of ranitidine
HU213598B (en) * 1994-10-18 1997-08-28 Ge Lighting Tungsram Rt One-side socketed discharge lamp
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
GB9715423D0 (en) 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
ES2382993T3 (es) 2006-07-21 2012-06-15 Lyne Laboratories, Inc. Composición líquida de acetato de calcio
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735587A1 (de) * 1977-08-06 1979-02-15 Sandoz Ag Stabile loesungen und verfahren zu deren herstellung
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest
CA1211374A (en) * 1982-05-14 1986-09-16 Eszter Cholnoky Pharmaceutical compositions containing more active ingredients
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
DK652787A (da) 1988-06-13
AU607451B2 (en) 1991-03-07
FR2608921A1 (fr) 1988-07-01
YU224587A (en) 1990-10-31
DE3742127A1 (de) 1988-10-06
DK652787D0 (da) 1987-12-11
IE60618B1 (en) 1994-07-27
FR2608921B1 (fr) 1991-04-12
AU8244487A (en) 1988-06-16
ATA327387A (de) 1992-05-15
IT1211967B (it) 1989-11-08
GB8728957D0 (en) 1988-01-27
GB8629781D0 (en) 1987-01-21
CA1303993C (en) 1992-06-23
HK19095A (en) 1995-02-17
ZA879338B (en) 1989-02-22
GB2198352A (en) 1988-06-15
CZ281599B6 (cs) 1996-11-13
NL194431B (nl) 2001-12-03
PH25390A (en) 1991-06-03
SE8704952D0 (sv) 1987-12-11
KR960008228B1 (ko) 1996-06-21
IT8748698A0 (it) 1987-12-11
IE873367L (en) 1988-06-12
AT395373B (de) 1992-12-10
SE504333C2 (sv) 1997-01-13
NL8703000A (nl) 1988-07-01
IL84795A0 (en) 1988-05-31
JPS63215622A (ja) 1988-09-08
CS403791A3 (en) 1992-08-12
YU46561B (sh) 1993-11-16
BE1000624A5 (fr) 1989-02-21
DE3742127C2 (de) 1997-08-28
JP2590156B2 (ja) 1997-03-12
US5068249A (en) 1991-11-26
NL194431C (nl) 2002-04-04
SE8704952L (sv) 1988-06-13
DK167842B1 (da) 1993-12-27
NZ222879A (en) 1990-08-28
CH675207A5 (ko) 1990-09-14
GB2198352B (en) 1990-11-28

Similar Documents

Publication Publication Date Title
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
KR880007060A (ko) 제약 조성물
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR900015737A (ko) 배합물
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
KR890015745A (ko) 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법
KR970025615A (ko) 암 전이 억제제
KR880007073A (ko) 의 약 품
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR880009654A (ko) 아세트알데히드의 독성을 감소시키는 조성물 및 방법
ATE65395T1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
KR890004705A (ko) 항바이러스성 제제
KR920003981A (ko) 항염증성 조성물
KR880004810A (ko) 소화성 궤양 치료제
KR900015732A (ko) 경구용 제제
KR980002033A (ko) 트리아졸 유도체 또는 그 염
KR950010880A (ko) 안정한 복합비타민 내복액제
KR910004190A (ko) 온단세트론의 신규 의학 용도
KR870001144A (ko) Nn-디메틸에틸옥사이드가 함유된 약제조성물 및 그의 생산방법
KR900701263A (ko) 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100531

Year of fee payment: 15

EXPY Expiration of term